Anti-Fungal Treatment Companies | Market Research Future

Top Industry Leaders in the Antifungal Treatment Market

Antifungal Treatment Key Companies Disclaimer: List of key companies in no particular orderLatest Anti-fungal treatment Companies Update

Aug 2023: Gilead Sciences announced that just one month after the firm canceled a late-stage study due to effectiveness concerns, the US health government put a clinical hold on tests of its blood cancer treatment. When the corporation acquired Forty-Seven Inc. for $4.9 billion in March 2020, it acquired access to the medication magrolimab. According to the business, the U.S. Food and Drug Administration (FDA) has stopped screening and enrolling new study participants. However, patients who are currently enrolled in studies may still get treatment. According to the business, studies on magrolimab in solid tumors will proceed unaffected by the FDA's action. The medicine was being studied by the business to treat individuals who have a greater chance of myelodysplastic syndromes, a rare category of illnesses causing bone marrow loss, in conjunction with azacitidine chemotherapy.

Oct 2023: Even after worries about potential liver damage surfaced, Merck KGaA stated that its experimental multiple sclerosis treatment can still be a "blockbuster," an industry word for yearly sales exceeding $1 billion. As the front-runner in the quest to acquire permission for a more focused kind of MS medication, Merck's stock price fell in April after the US regulators announced that they were stopping the enrollment of new patients in a trial evaluating the medication evobrutinib. The afflicted two patients did not exhibit any symptoms and did not require medical attention, the business maintained at the time, even though the U.S. Food and Drug Administration had referenced laboratory evidence suggesting drug-induced liver impairment.

List of Anti-fungal treatment Key companies in the market